Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 447

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group Study AALL0031

Open access
Schultz, K R, Carroll, A, Heerema, N A, Bowman, W P, Aledo, A, Slayton, W B, Sather, H, Devidas, M, Zheng, H W, Davies, S M, Gaynon, P S, Trigg, M, Rutledge, R, Jorstad, D, Winick, N, Borowitz, M J, Hunger, S P, Carroll, W L, Camitta, B, from the Children’s Oncology Group·2014·Leukemia

Abstract

We previously reported preliminary findings that post induction imatinib mesylate (340 mg/m2/day), in combination with intensive chemotherapy, resulted in outcomes similar to blood and marrow transplant (BMT) for pediatric patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). We now report 5-year outcomes of imatinib plus intensive chemotherapy in 91 children (1–21 years) with and without allogeneic BMT (N=91). We explore the impacts of additional chromosomal abnormalities and minimal residual disease (MRD) by flow cytometry on outcomes. The 5-year disease-free survival was similar for Cohort 5 patients, treated with chemotherapy plus imatinib (70%±12%, n=28), sibling donor BMT patients (65%±11%, n=21) and unrelated donor BMT patients (59±15%; P=0.60, n=13). Patients with additional cytogenetic abnormalities had worse outcomes (P=0.05). End induction (pre-imatinib) MRD was not prognostic for Cohort 5 or allogeneic BMT patients, although limited by small numbers. The re-induction rate following relapse was similar to other higher-risk ALL groups. Longer-term follow-up confirms our initial observation of substantially good outcomes for children and adolescents with Ph+ ALL treated with imatinib plus intensive chemotherapy with no advantage for allogeneic BMT.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/leu.2014.30

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 447

Metadata

Authors
Schultz, K. R., Carroll, A., Heerema, N. A., Bowman, W. P., Aledo, A., Slayton, W. B., Sather, H., Devidas, M., Zheng, H. W., Davies, S. M., Gaynon, P. S., Trigg, M., Rutledge, R., Jorstad, D., Winick, N., Borowitz, M. J., Hunger, S. P., Carroll, W. L., Camitta, B., & from the Children’s Oncology Group
Venue
Leukemia
Published
2014-01-20
Volume
28
Issue
7
Pages
1467-1471
ISSN
  • 0887-6924 (ISSN-L)
  • 1476-5551
OpenAlex
W2047597898
Cited by
447
References
18
FWCI
43.20
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group Study AALL0031. https://app.cochat.ai/papers/10.1038/leu.2014.30
The paper
Schultz, K. R., Carroll, A., Heerema, N. A., Bowman, W. P., Aledo, A., Slayton, W. B., Sather, H., Devidas, M., Zheng, H. W., Davies, S. M., Gaynon, P. S., Trigg, M., Rutledge, R., Jorstad, D., Winick, N., Borowitz, M. J., Hunger, S. P., Carroll, W. L., Camitta, B., & from the Children’s Oncology Group. (2014). Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group Study AALL0031. Leukemia. https://doi.org/10.1038/leu.2014.30

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.